We introduce a new category of nanoparticle-based T(1) MRI
contrast agents (CAs) by encapsulating paramagnetic chelated
gadolinium(III), i.e.,
Gd(3+)·DOTA, through supramolecular assembly of molecular building blocks that carry complementary molecular recognition motifs, including
adamantane (Ad) and β-
cyclodextrin (CD). A small library of
Gd(3+)·DOTA-encapsulated supramolecular nanoparticles (
Gd(3+)·DOTA⊂SNPs) was produced by systematically altering the molecular building block mixing ratios. A broad spectrum of relaxation rates was correlated to the resulting
Gd(3+)·DOTA⊂SNP library. Consequently, an optimal synthetic formulation of
Gd(3+)·DOTA⊂SNPs with an r(1) of 17.3 s(-1) mM(-1) (ca. 4-fold higher than clinical
Gd(3+) chelated complexes at high field strengths) was identified. T(1)-weighted imaging of
Gd(3+)·DOTA⊂SNPs exhibits an enhanced sensitivity with a contrast-to-noise ratio (C/N ratio) ca. 3.6 times greater than that observed for free
Gd(3+)·DTPA. A
Gd(3+)·DOTA⊂SNPs
solution was injected into foot pads of mice, and MRI was employed to monitor dynamic lymphatic drainage of the
Gd(3+)·DOTA⊂SNPs-based CA. We observe an increase in signal intensity of the brachial lymph node in T(1)-weighted imaging after injecting
Gd(3+)·DOTA⊂SNPs but not after injecting
Gd(3+)·DTPA. The MRI results are supported by ICP-MS analysis ex vivo. These results show that
Gd(3+)·DOTA⊂SNPs not only exhibits enhanced relaxivity and high sensitivity but also can serve as a potential tool for diagnosis of
cancer metastasis.